|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.
|
10212304 |
1999 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We recently demonstrated that the TNFalpha pathway contributes to the pathogenesis of sporadic PD using a genetic approach.
|
12203044 |
2002 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study investigated the frequency of polymorphism located in the critical promoter region of the proinflammatory cytokine genes: interleukin (IL)-2, IL-6, IL-8, and tumor necrosis factor alpha (TNF-alpha) within a cohort of patients with PD in comparison to a group of healthy elderly individuals.
|
15120188 |
2004 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conducted a case-control study in a cohort of 369 PD cases and another cohort of 326 ethnically matched controls to investigate the association of tumor necrosis factor-alpha (TNF-alpha) promoter single nucleotide polymorphisms (SNPs) with the risk of PD.
|
17192953 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
We conducted a case-control study in a cohort of 369 PD cases and another cohort of 326 ethnically matched controls to investigate the association of tumor necrosis factor-alpha (TNF-alpha) promoter single nucleotide polymorphisms (SNPs) with the risk of PD.
|
17192953 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
We observed a greater than 2-fold increased risk of PD among carriers of the homozygous variant genotype of IL-1beta-511 (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.27-4.02) and the homozygous variant genotype of TNF-alpha-308 (OR, 2.49; 95% CI, 0.90-6.85) and an almost 3-fold increased risk among carriers of the homozygous variant genotype for either or both polymorphisms (OR, 2.92; 95% CI, 1.66-5.16).
|
17562931 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We observed a greater than 2-fold increased risk of PD among carriers of the homozygous variant genotype of IL-1beta-511 (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.27-4.02) and the homozygous variant genotype of TNF-alpha-308 (OR, 2.49; 95% CI, 0.90-6.85) and an almost 3-fold increased risk among carriers of the homozygous variant genotype for either or both polymorphisms (OR, 2.92; 95% CI, 1.66-5.16).
|
17562931 |
2007 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Programmed cell death of the nigro-striatal dopamine neurons in PD has been suggested from the following findings on postmortem brains: (1) increased levels of pro-inflammatory cytokines such as TNF-alpha and IL-6; (2) increased levels of apoptosis-related factors such as TNF-alpha receptor R1 (p 55), soluble Fas and bcl-2, and increased activities of caspases 1 and 3; and (3) decreased levels of neurotrophins such as brain-derived nerve growth factor (BDNF).
|
17982884 |
2007 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
For the first time, the multilocus approach by the set-association method has been applied for the analysis of a cluster of five genes [tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), IL-8, IL-1alpha and IL-10] involved in the brain neuroinflammatory pathway in Parkinson's disease (PD), in a well-defined group of 197 PD patients and 173 control subjects from Spain.
|
18284424 |
2008 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results from our study revealed that the TNF -308AA genotype might increase the risk of early onset of PD.
|
18362084 |
2008 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Peripheral cytokines profile in Parkinson's disease.
|
18678243 |
2009 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Although there was a tendency for hypomethylation in PD, our analysis of the 10 CpGs in the TNF-alpha core promoter region (-258 to -35 relative to the TSS) revealed no particular pattern in PD patients compared to control and identified no particular hypomethylated position in cortex or SNpc DNA.
|
18930140 |
2008 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To test the hypothesis whether the methylation state of the TNF-alpha promoter contributes to increased expression of TNF-alpha in PD we compared DNA from different brain regions (substantia nigra pars compacta (SNpc) and cortex) of PD patients and neurologically healthy, age and sex matched controls by bisulfite sequencing of the TNF-alpha promoter region.
|
18930140 |
2008 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Adenosine concentration and TNF-alpha levels were increased in plasma of patients with PD.
|
19776336 |
2010 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that the cytokine gene polymorphisms we investigated are not related to the development of PD in the Italian population; further studies are warranted to clarify the role of the TNF-α-308GG/IL-1β-511T+ combined genotype.
|
20880267 |
2011 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These promising findings provide compelling reasons to perform DN-TNF gene transfer studies in nonhuman primates with the long-term goal of using it in the clinic to prevent the delayed and progressive degeneration of DA neurons that gives rise to motor symptoms in PD.
|
20959812 |
2011 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Table 1 Biochemical Alterations in Substantia Nigra of Parkinson's Disease Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.
|
21318773 |
2001 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease.
|
21472005 |
2011 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway.
|
23169921 |
2012 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the potent antioxidant fraction of UD attenuated the pro-inflammatory cytokines (TNF-α and IL-β) and restored the level of dopamine and its metabolites in MPTP-induced PD in rats.
|
27624385 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neuroinflammatory mechanisms mediated by activated glial and cytokines (TNF-α, IL-1β) might contribute to neuronal degeneration leading to Alzheimer's (AD) and Parkinson's disease (PD).
|
27776205 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results showed that baicalein treatment improved motor impairments, attenuated brain damage, suppressed the production of proinflammatory cytokines (tumor necrosis factor α (TNF-α), and interleukin 6 (IL-6)), modulated the astrocytes and microglia activation, and blocked the activation of nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signals in rotenone-induced rats of PD.
|
28623717 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the levels of oxidative stress, tumor necrosis factor (TNF)-α and interleukin (IL)-1β are all reduced significantly in PD mice and the CAR-25 mg kg<sup>-1</sup> DA group in comparison with that in 6-OHDA-lesioned mice with saline and 6-OHDA-lesioned mice, as well as the Tyrosine hydroxylase-immunoreactive (TH-ir) density increased (p < 0.01).
|
28726961 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, linear discriminant analysis revealed that serum TNF and CSF α-synuclein discriminated between PD and HC with a minimum of 82% sensitivity and 83% specificity.
|
28821274 |
2017 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Logistic binary regression analysis showed that the genetic background leading to higher TNF-α expression confers a higher risk to develop PD earlier.
|
28844731 |
2017 |